ProCE Banner Activity

Phase I/II Study of Venetoclax + Dexamethasone in Patients With t(11;14) R/R Multiple Myeloma

Slideset Download
Conference Coverage
Initial findings from this preliminary study indicate that combined treatment with venetoclax and dexamethasone is safe and active in patients with t(11;14) R/R MM.

Released: December 17, 2019

Expiration: December 15, 2020

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company